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of Hong Kong, Hong Kong, 2University of Hong Kong, Hong Kong SAR, China  
Nasopharyngeal carcinoma (NPC) is common in southern Chinese. 
Radiotherapy (RT) is effective in the control of early-stage NPC but the 
response is poorer in advanced disease. Adjuvant chemotherapy has been 
advocated to manage advanced cases. However, the use of additional 
chemotherapy may expose patients to a greater risk of oral candidal 
infections. Objective: To compare the oral yeast profile in NPC patients 
receiving RT only (RTO) and radiotherapy plus chemotherapy (RTCH) before 
RT, then 2-months and 6-months after RT. Methods: 39 patients receiving 
RTO and 36 receiving RTCH were recruited prior to treatment. Selective 
culture of oral rinse samples was carried out to isolate, quantify and speciate 
yeast recovery using API kits. Wilcoxon signed ranks, McNemar, Mann-
Whitney and Chi-square tests were used to compare changes over time and 
between groups. Results: At baseline, both groups exhibited no statistical 
difference in oral candidiasis (RTO: 10.3%; RTCH: 5.6%), oral yeast 
colonization (RTO: 23.1%; RTCH: 19.4%) or mean yeast counts (RTO: 
290±208 cfu; RTCH: 49±39 cfu). At 2-month recall, both groups presented 
with a significant increase (p<0.01) in oral candidiasis (RTO: 25.6%; RTCH: 
38.9%), oral yeast colonization (RTO: 64.1%; RTCH: 44.4%) and mean yeast 
counts (RTO: 4145±2149 cfu; RTCH: 1169±317 cfu). No significant 
differences were found between the two groups. 38% (RTO) and 25% (RTCH) 
of subjects were infected with non-C. albicans yeasts. No significant changes 
were found between 2- and 6-month recall and no significant differences in 
yeast profile were observed between the two groups at 6-month evaluation. 
Conclusion: Adjuvant chemotherapy did not affect the oral yeast profile in the 
short-term after treatment for NPC. Non-C. albicans yeasts appeared to play a 
significant role in oral candidial infection in NPC patients. Supported by CRCG-
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